ABUS vs EFX · P/E 5.4, rev $6.2M vs P/E 54, rev $5.68B
Arbutus Biopharma Corp (ABUS) versus Equifax Inc (EFX) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Equifax Inc (EFX) is a consulting services company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported EFX revenue for 2024-12-31 was $5.68B. Net income was $607.3M. Revenue was up 7.9% from 2023-12-31 to 2024-12-31. EFX currently screens at market cap $33.00B and trailing P/E 54.0.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. EFX currently screens at market cap $33.00B and trailing P/E 54.0.
Not investment advice. Open the ABUS and EFX stock pages for the full models.
Not investment advice.